Navigation Links
Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P

Pharma company Lupin Ltd today said it has received approval from the Drugs Controller General (India) (DCGI) to conduct Phase II clinical trials for the molecule LL-42 18 (Desoside-P).//

The company received permission to continue Phase II clinical trials on the Psoriasis pure compound, LL-42 18, after DCGI found the clinical Phase I data of the molecule to be satisfactory.

Lupin informed the Bombay Stock Exchange that it intends to begin clinical trials at 5-6 centres immediately.

'We are delighted that our Phase I data has been found to be satisfactory for us to proceed with further clinical trials. We are very excited with taking the molecule forward and look forward to meeting this otherwise unmet market need,' Company Chairman Desh Bandhu Gupta said.

LL-4218, a pure molecule, is obtained from a plant source and is intended for the treatment of chronic stable plaque type psoriasis. This molecule's novel mechanism of action leads to marked psoriatic lesion improvement without any toxic effects.

The company said it also has three other new chemical entities in various stages of clinical trials.

Source:PTI News
'"/>




Page: 1

Related medicine news :

1. Lupin flour may cause peanut allergy like reactions
2. Lupin Gets USFDA Approval For Quinapril Tablets
3. US Court Rules Against Lupin in Ramipril Patent Case
4. Lupin Gets USFDA Approval for Meloxicam
5. Lupin Gets Tentative Nod from FDA for Antidepressant Drug
6. SARS-Free Taiwan to Mark End Phase of Global Fight
7. Spray on contraceptive clears Phase I trial
8. Phase 3 trials of two multi-kinase inhibitors against cancer
9. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
10. Phase II trails of new HIV vaccine to be held in South Africa
11. FDA approves Phase 0 trial which tests experimental drugs on humans
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health Solutions, ... raised $6.0 million in an initial round of funding. The round was led ... their caregivers can receive far better care through the application of the best ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: November ... Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon Kleyne, ... Water, Global Climate Change and Your Health radio program syndicated on Voice of ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... now offer a comprehensive in-house dental plan for all patients. Understanding that budget ... plan that gives patients a number of perks, including discounts on many valuable ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... mental health treatment has announced the opening of a new eating disorder treatment ... and intensive outpatient treatment for adults and adolescents, both males and females ages ...
(Date:11/30/2016)... Warrington, U.K. (PRWEB) , ... November 30, 2016 ... ... to address the tech functions and stylish design wanted by today’s consumers at ... , Cronovo Co-Founder Darin Philip says the new watch is “a game changer” ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec 1, 2016 Research ... "Drug Delivery in Cancer - Technologies, Markets and Companies" ... , ... challenge in management of cancer The market value of ... Cancer market estimates from 2015-2025 are given according to organs involved ...
(Date:12/2/2016)... 2016 Around the corners of world, cancer ... habitable land present over earth. Cancer has become one ... a life time this is because of the increasing ... Given the steady increase in global cancer incidence with ... healthcare costs of treatment, there is increasing interest in ...
(Date:12/2/2016)... Dec. 2, 2016 Allergan plc (NYSE: ... information on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a ... the Company will repurchase $10 billion of its ordinary shares. ...
Breaking Medicine Technology: